Digital therapeutics company Big Health announced it acquired Limbix, a maker of prescription digital therapeutics aimed at treating depression in teens and young adults.
Limbix is the creator of SparkRx, a PDTx that uses the principles of cognitive behavioral therapy to address depression in teens and young adults ages 13 to 22.
The self-guided CBT-based treatment was released in October 2021...
The National Institute for Health and Care Excellence (NICE) has recommended the Sleepio app as an effective alternative to sleeping pills.
In its guidance, NICE states the app, created by digital therapeutics (DTx) firm Big Health, is a safe and effective treatment for people suffering from insomnia.
It adds that the app could save the NHS money and reduce prescriptions of medicines such as...
Adults in Scotland can now access Big Health’s digital therapeutics for anxiety and insomnia for free via the NHS.
People across all 14 NHS Scotland health board areas are able to self-refer or visit their GP to receive cognitive behavioural therapy (CBT) through the Daylight and Sleepio apps.
In October last year, the Scottish Government made the Big Health apps available across five NHS...
Using Sleepio, a digital therapeutic to reduce insomnia, improved sleep, anxiety and depression more than other psychological interventions alone, according to a study published in Behaviour Research and Therapy.
The study was partially funded by Big Health, Sleepio’s parent company, and most authors were Big Health employees or paid consultants.
TOP-LINE DATA
Patients who used Sleepio achieved...
A recent mathematical simulation model found that, compared to other insomnia interventions like group cognitive behavioral therapy or pharmacotherapy, digital CBT delivered via Big Health's Sleepio was more cost-effective due to lower expenditures.
The research was funded by Big Health, and conducted by researchers from Johns Hopkins, the University of California, San Francisco, and the digital...
The use of cognitive-behavioral therapy interventions, such as Big Health’s Sleepio program, has been found to improve both sleep and mental health in individuals with insomnia and clinically significant depressive symptoms, according to new research published in the Journal of Sleep Research.
Sleepio is a digital sleep-improvement program that offers personalized treatment base on a user’s...
Big Health, maker of digital health apps targeting poor sleep, worry and anxiety, has announced a $39 million Series B raise.
Gilde Health and Morningside Ventures headlined the funding. Samsung NEXT also participated in the raise, as did prior backers Kaiser Permanente Ventures and Octopus Ventures.
WHAT THEY DO
Big Health's two major digital health products Sleepio and Daylight are digital...
Investment into mental health technology has boomed, reaching £580 million in 2019, according to a study by early stage investor Octopus Ventures.
The research, based on analysis of the latest Pitchbook data, shows an almost five-fold increase in mental health tech investment in the last six years, rising from £120 million in 2014.
Octopus says this trend is down to corporates increasingly...
London and San Francisco-based digital therapeutics company Big Health has tapped Sir Bruce Keogh, former medical director for NHS England, to join its Advisory Board in an effort to expand access to their products.
Sir Bruce stepped down after 10 years in the national role at the end of 2017 and took up a new position as chair of the Birmingham Women’s and Children’s NHS Foundation Trust....
When it comes to health apps, concerns around data transparency and privacy or the lack of scientific evidence or peer-reviewed studies to back up their use have long plagued the digital health world. Only last week, period tracking platforms came under fire after a report from UK-based research group Privacy International found that some apps were sharing users’ personal information with...
